BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38702396)

  • 1. Recent developments and future directions of first-line systemic therapy combined with immunotherapy for advanced or metastatic urothelial carcinoma: a historical perspective on treatment evolution.
    Kawashima A; Ishizuya Y; Yamamoto Y; Kato T; Hatano K; Nonomura N
    Int J Clin Oncol; 2024 Jun; ():. PubMed ID: 38850448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapies After Progression on Enfortumab Vedotin and Pembrolizumab: Navigating Second-line Options for Metastatic Urothelial Carcinoma in the New Treatment Landscape.
    Brown JR; Koshkin VS
    Eur Urol Focus; 2024 May; ():. PubMed ID: 38797658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Refractory insulin resistance and hemophagocytic lymphohistiocytosis following enfortumab vedotin treatment: A case report.
    Rossignon P; Nguyen LDK; Boegner P; Ku J; Herpain A
    Mol Clin Oncol; 2024 Jun; 20(6):44. PubMed ID: 38799283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The evolving treatment landscape of metastatic urothelial cancer.
    Roviello G; Santoni M; Sonpavde GP; Catalano M
    Nat Rev Urol; 2024 May; ():. PubMed ID: 38702396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review.
    Lavoie JM; Sridhar SS; Ong M; North S; Alimohamed N; McLeod D; Eigl BJ
    Oncologist; 2021 Aug; 26(8):e1381-e1394. PubMed ID: 34028134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma.
    Mansinho A; Cruz A; Marconi L; Pinto C; Augusto I
    Adv Ther; 2023 Oct; 40(10):4134-4150. PubMed ID: 37608243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of metastatic urothelial carcinoma: Current approach, emerging agents, and future perspectives.
    Iacovelli R; Cicala CM; Ciccarese C; Sacco E; Racioppi M; Bassi PF; Tortora G
    Urologia; 2023 Feb; 90(1):3-10. PubMed ID: 36537831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revisiting Treatment of Metastatic Urothelial Cancer: Where Do Cisplatin and Platinum Ineligibility Criteria Stand?
    Moussa MJ; Campbell MT; Alhalabi O
    Biomedicines; 2024 Feb; 12(3):. PubMed ID: 38540132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic treatment of advanced and metastatic urothelial cancer: The landscape in Australia.
    Gurney H; Clay TD; Oliveira N; Wong S; Tran B; Harris C
    Asia Pac J Clin Oncol; 2023 Dec; 19(6):585-595. PubMed ID: 37727139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study.
    Bamias A; Davis ID; Galsky MD; Arranz JÁ; Kikuchi E; Grande E; Del Muro XG; Park SH; De Giorgi U; Alekseev B; Mencinger M; Izumi K; Schutz FA; Puente J; Li JR; Panni S; Gumus M; Özgüroğlu M; Mariathasan S; Poloz Y; Bene-Tchaleu F; Lee C; Bernhard S; De Santis M
    Lancet Oncol; 2024 Jan; 25(1):46-61. PubMed ID: 38101431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
    Loriot Y; Matsubara N; Park SH; Huddart RA; Burgess EF; Houede N; Banek S; Guadalupi V; Ku JH; Valderrama BP; Tran B; Triantos S; Kean Y; Akapame S; Deprince K; Mukhopadhyay S; Stone NL; Siefker-Radtke AO;
    N Engl J Med; 2023 Nov; 389(21):1961-1971. PubMed ID: 37870920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
    Maiorano BA; Catalano M; Maiello E; Roviello G
    Front Oncol; 2023; 13():1254906. PubMed ID: 37781180
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.